Revenue · 2021–2025
Kiniksa Pharmaceuticals International revenue
$678M+60.1% · FY2025
Kiniksa Pharmaceuticals International (KNSA) reported $678M in revenue for fiscal 2025, +60.1% year on year.
Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2021–2025 compound annual growth +104.8%
Revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Kiniksa Pharmaceuticals International revenue |url=https://companiesranked.com/en/company/kiniksa-pharmaceuticals-international/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Kiniksa Pharmaceuticals International revenue. CompaniesRanked. https://companiesranked.com/en/company/kiniksa-pharmaceuticals-international/revenueBibTeX
@misc{companiesranked-en-company-kiniksa-pharmaceuticals-international-revenue-2026,
author = {{CompaniesRanked}},
title = {{Kiniksa Pharmaceuticals International revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/kiniksa-pharmaceuticals-international/revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-019168 · February 24, 2026
{{cite web |title=Kiniksa Pharmaceuticals International revenue — 10-K (0001104659-26-019168) |url=https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.